CC-4047 (Pomalidomide) for Graft vs. Host Disease

A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation

This study will test the safety and effectiveness CC-4047 (pomalidomide) in patients with advanced, steroid refractory graft-versus-host disease.

Study Overview

• Status: Completed
• Conditions: Graft vs Host Disease
• Intervention / Treatment: Drug: CC-4047

Detailed Description

Chronic Graft vs. Host Disease is a major complication after allogeneic hematopoietic stem cell transplantation developing in 30 - 70% of patients. It is a multisystem alloimmune and autoimmune disorder with a negative impact on quality of life and functional status, increased need for extended immunosuppression and is the leading cause of late transplant related mortality.

CC-4047 is a novel immune modulatory drug that is a thalidomide analog with a 4,000 fold greater inhibition of TNF-α production related to thalidomide. Several features of CC-4047 suggest that this drug may be useful in treating chronic GVHD including in vitro suppression of TNF-α production, increasing Th1 and stimulation of IL-12 and sIL-Rα.

This study is an open-label, single-arm, pilot study of efficacy and safety of CC-4047 in patients with advanced chronic GvHD who failed to achieve a response with high-dose corticosteroids or second line systemic immunosuppressive therapy.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Missouri
    • St. Louis, Missouri, United States, 63122
      • Washington University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Patient must meet all of the following inclusion criteria:

• Must be greater than or equal to 18 years of age at the time of consent.
• Must be able to adhere to the study visit schedule and other protocol requirements.
• Chronic graft versus host disease (GHVD) developing after allogeneic hematological stem cell transplantation diagnosed using NIH criteria for diagnosis and staging of chronic GvHD (including both "classic chronic GvHD" and "overlap syndrome")
• Must have moderate or severe chronic GvHD according to Global Staging System for Chronic GvHD or mild chronic GvHD with platelet count less than 100 x 109/L
• Must have failed to achieve response to high dose corticosteroid (average 0.5 mg/kg/day prednisone or equivalent for greater than or equal to 8 weeks), or have failed second line systemic immunosuppressive therapy.
• If taking corticosteroids at the time of enrollment, must be on stable or tapering schedule without corticosteroid pulses in the preceding 8 weeks.
• If taking secondary systemic immunosuppressive therapy at the time of enrolment, must be on stable or tapering schedule in the preceding 4 weeks.
• Karnofsky performance score (KPS) greater than or equal to 60%.
• Life expectancy greater than or equal to 3 months.
• Female of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse for at least 28 days before starting study drug, while participating in the study, and for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.
• FCBP must agree to pregnancy testing and contraceptive counseling every 28 days during the study. FCBP must also refrain from donating blood and/or egg while participating in the study and for at least 28 days after discontinuation from this study
• FCBP must have two negative pregnancy tests (sensitivity of at least 25 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to the start of study drug.
• Must agree to abstain from breastfeeding during study participation and for at least 28 days after study drug discontinuation.
• Male Subjects must agree to complete abstinence or to use a condom during sexual contact with with a pregnant female or a female of childbearing potential while participating in the study and for at least 90 days following study drug discontinuation even if he has undergone a successful vasectomy
• Must agree to counseling about sexual contact and the potential risks of fetal exposure to pomalidomide every 28 days.
• Male subjects will be warned that sharing study drug is prohibited
• Must agree to abstain from donating blood for at least 28 days following discontinuation of the study drug.
• Must agree to abstain from donating semen or sperm during study participation and for at least 90 days after study drug discontinuation.
• Must agree that if a pregnancy or a positive pregnancy test does occur in a the partner of a male study subject during study participation, the investigator must be notified immediately
• Patients must agree to not share study drug with anyone during participation in the study.
• Must understand and voluntarily sign an informed consent form, or must have a legally authorized representative who is able and willing to voluntarily sign an informed consent form on behalf of the patient.

Exclusion Criteria:

• Pregnant or lactating females.
• New immunosuppressive therapy started within the preceding 4 weeks.
• Extracorporeal photopheresis within the preceding 3 months.
• Hypersensitivity to any immune modulator drug (IMiD™).
• Unable to take prophylactic anticoagulation.
• Any condition which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Acute, persistent, recurrent or late-onset acute GvHD defined by NIH criteria.

• Any of the following laboratory values at registration:

  • absolute neutrophil count (ANC) less than 1.0 x 109/L,
  • platelets less than 75 x 109/L, or
  • creatinine clearance less than 50 mL/min (Cockroft-Gault formula).
• Uncontrolled infection requiring systemic antibiotics.
• Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection.
• Known uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction less than 40% (an ECHO should be performed as clinically indicated)
• Recurrence of cancer for which the transplant was done except for presence of minimal residual disease by PCR.
• Other cancer less than or equal to 2 years prior study-entry except:
• Basal cell carcinoma of the skin,
• Squamous cell carcinoma of the skin,
• Carcinoma in situ of the cervix,
• Carcinoma in situ of the breast, or
• Prostate cancer (Tumor, Node, Metastasis [TNM] stage T1a or T1b)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CC-4047 Arm; CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).	Drug: CC-4047; Other Names: Pomalidomide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response (Complete Response + Partial Response + Other)	CR is defined as complete resolution in all of signs and symptoms at all affected organs and tissues; PR is defined as improvement in greater than or equal to 1 organ/tissue with no progression in any other affected organ/tissue; Improvement in chronic GvHD symptoms less than what meets the definition of a PR is defined as other; Progressive disease is defined as failure of therapy to control chronic GvHD despite increasing the dose of primary therapy or adding second line treatments; No response is defined as no change in disease.	1 year after last dose of CC-4047

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety as Measured by the Most Common Adverse Effects and Reasons for Dose Reductions or Study-discontinuation	-Toxicities will be graded according to the NCI CTCAE v3.0.	30 days after last dose of CC-4047 or until resolution of event

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Investigators: Principal Investigator: John F. DiPersio, M.D., Ph.D., Washington Univerisity School of Medicine

Publications and helpful links

Helpful Links

• Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start: February 1, 2009
• Primary Completion (Actual): October 1, 2010
• Study Completion (Actual): October 1, 2011

Study Registration Dates

• First Submitted: October 7, 2008
• First Submitted That Met QC Criteria: October 8, 2008
• First Posted (Estimate): October 10, 2008

Study Record Updates

• Last Update Posted (Estimate): February 25, 2016
• Last Update Submitted That Met QC Criteria: January 28, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Graft vs Host Disease; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Pomalidomide
• Other Study ID Numbers: 08-1093 / 201106102